Evaluation of the use of empirical treatment for Covid-19 with chloroquine/hydroxychloroquine, during the first wave in Ceará, in patients admitted to a hospital unit
DOI:
https://doi.org/10.33448/rsd-v11i16.37364Keywords:
Covid-19; Chloroquine; Hydroxychloroquine; Azithromycin; Corticosteroids.Abstract
In late December 2019, an outbreak of an emerging disease (Covid-19) due to a novel coronavirus (called SARS-CoV-2) quickly turned into a pandemic. The reassessment of drugs for use as antiviral treatments was one of the first therapeutic initiatives, especially chloroquine/hydroxychloroquine. A retrospective study of the medical records of patients hospitalized with Covid-19 from March to April 2020 and correlated analysis of therapy with Chloroquine/Hydroxychloroquine, Azithromycin, Oseltamivir and corticosteroids was performed. A total of 122 patients were evaluated, with a high percentage of patients admitted to the ICU (41.8%). The main symptoms were: dyspnea (68.9%), fever (84.4%) and cough (81%). Total mortality was 11.5% (N=14), with a mean age of 73 years (var 55-87). Patients discharged from the hospital had a mean age of 49.7 years. A high report of comorbidities associated with hospital admission was detected, mainly SAH, DM, cardiological and neuropsychiatric diseases. The use of the medications chloroquine or hydroxychloroquine had no impact on mortality (p=0.55), nor was the use of azithromycin (p=0.78) or corticosteroids (p=0.3). Patients who required ICU admission had lower mean hemoglobin levels compared to admission, as well as increased inflammatory markers (leukocytes, platelets, D-dimers, TGO, CRP and LDH). It was concluded that the use of chloroquine/hydroxychloroquine was ineffective in terms of mortality.
References
Al-Bari, M. A. (2015). Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 70: 1608–21. 10.1093/jac/dkv018.
Alimohamadi, Y., Sepandi, M., Taghdir, M. & Hosamirudsari, H. (2020). Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 61: E304-E312. https://doi.org/10.15167/2421-4248/ jpmh2020.61.3.1530
Axfors, C., Schmitt, A.M., Janiaud, P. et al. (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 12, 2349. https://doi.org/10.1038/s41467-021-22446-z
Bosseboeuf, E., Aubry, M., Nhan, T., de Pina, J.J., Rolain, J.M., Raoult, D. et al. (2018). Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir 10:6–11. 10.4172/1948-5964.1000173.
Boulos, A., Rolain, J.M., Raoult, D. (2004). Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 48:747–52. 10.1128/aac.48.3.747-752.2004.
Chan, J.F., Yuan, S., Kok, K.H., et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet 395: 514–23.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) [Internet]. 2020;6736(20):1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32007143
Chen Z-M, Fu J-F, Shu Q, Chen Y-H, Hua C-Z, Li F-B, et al. (2020). Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32026148.
Colson, P., Rolain, J.M., Raoult, D. (2020). Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 105923. 10.1016/j.ijantimicag.2020.105923.
CSSE. (2022). COVID-19. Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://coronalevel.com/Brazil/Ceará/.Acesso em 1 de janeiro de 2022.
de Souza, W.M., Buss, L.F., Candido, D.D.S., Carrera, J.P., Li, S., Zarebski, A.E., Pereira, R.H.M., Prete, C.A. Jr, de Souza-Santos, A.A., Parag, K.V., Belotti, M.C.T.D., Vincenti-Gonzalez, M.F., Messina, J., da Silva Sales, F.C., Andrade, P.D.S., Nascimento, V.H., Ghilardi, F., Abade, L., Gutierrez, B., Kraemer, M.U.G., Braga, C.K.V. et al. (2020). Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav. Aug;4(8):856-865. 10.1038/s41562-020-0928-4. Epub 2020 Jul 31. PMID: 32737472.
Falavigna, M., Colpani, V., Stein, C., Azevedo, L., Bagattini, A. M., Brito, G. V., Chatkin, J. M., Cimerman, S., Corradi, M., Cunha, C., Medeiros, F. C., Oliveira Junior, H. A., Fritscher, L. G., Gazzana, M. B., Gräf, D. D., Marra, L. P., Matuoka, J. Y., Nunes, M. S., Pachito, D. V., Pagano, C., … Dal-Pizzol, F. (2020). Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Revista Brasileira de terapia intensiva, 32(2), 166–196. https://doi.org/10.5935/0103-507x.20200039
Fenollar, F., Puéchal, X., Raoult, D. Whipple's disease. (2007). N Engl J Med 356:55–66. 10.1056/NEJMra062477.
Gao, J., Tian, Z., Yang, X. (2020). Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. Feb 19 [Epub ahead of print]. 10.5582/bst.2020.01047.
Gao, Q., Hu, Y., Dai, Z. (2020). The epidemiological characteristics of 2019 novel coronavirus diseases (COVID-19) in Jingmen, Hubei, China. medRxiv; 10 mar. https://www.medrxiv. org/content/10.1101/2020.03.07.20031393v1.
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., & Wang, L. (2020). Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. Journal of medical virology, 92(7), 791–796. https://doi.org/10.1002/jmv.25770
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Kahn J. S., McIntosh K. (2005). History and recent advances in coronavirus discovery. Pediatr. Infect. Dis. J. 24 S223–S227. 10.1097/01.inf.0000188166.17324.60 discussion S226
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264–8. 10.1016/j.bbrc.2004.08.085.
Lagier, J.C., Fenollar, F., Lepidi, H., Giorgi, R., Million, M., Raoult, D. (2014). Treatment of classic Whipple's disease: from in vitro results to clinical outcome. J Antimicrob Chemother 69:219–27. 10.1093/jac/dkt310.
Li ,W., Moore, M.J., Vasilieva, N., et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426: 450 – 454.
Lima, D.L.F.; Dias, A.A., Rabelo, R.S., Cruz, I.D., Costa, S.C., Nigri, F.M.N., Neri, J.R. (2020). Covid-19 in the State of Ceará: behaviors and beliefs in the arrival of the pandemic. Ciênc. saúde coletiva 25 (5) • May 2020 • https://doi.org/10.1590/1413-81232020255.07192020
Masters P. S., Perlman S. (2013). “Coronaviridae,” in Fields Virology, eds Knipe D. M., Howley P. M., Cohen J. I. (Philadelphia, PA: Lippincott Williams & Wilkins).
Mehra, M.R., Desai, S.S., Ruschitzka, F., Patel, A.N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The lancet, Published online May 22, https://doi.org/10.1016/S0140-6736(20)31180-6
Ranganathan, P., & Aggarwal, R. (2018). Study designs: Part 1 - An overview and classification. Perspectives in clinical research, 9(4), 184–186. https://doi.org/10.4103/picr.PICR_124_18
Raoult, D., Drancourt, M., Vestris, G. (1990). Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 34:1512–4. 10.1128/aac.34.8.1512.
Raoult, D., Houpikian, P., Tissot Dupont, H., Riss, J.M., Arditi-Djiane, J., Brouqui, P. (1999). Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 159:167–73. 10.1001/archinte.159.2.167.
Rolain, J.M., Colson, P., Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30:297–308. 10.1016/j.ijantimicag.2007.05.015.
Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., et al. (2019). From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11:59. 10.3390/v11010059
Organização Pan-Americana De Saúde. Folha informativa – COVID-19 (doença causada pelo novo coronavírus). (2020).: https://www.paho.org/bra/index.php?option=com_content&view=article&id=6 101:covid19&Itemid=875.
Piret, J, Boivin, G. (2021). Pandemics Throughout History. Front Microbiol. Jan 15;11:631736. 10.3389/fmicb.2020.631736. Erratum in: Front Microbiol. 2022. 13:988058.
Richardson S., Hirsch J. S., Narasimhan M., Crawford J. M., McGinn T., Davidson K. W., et al. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323 2052–2059. 10.1001/jama.2020.6775
Rowley A. H., Shulman S. T., Arditi M. (2020). Immune pathogenesis of COVID-19-related multisystem inflammatory syndrome in children (MIS-C). J. Clin. Invest. 130 5619–5621. 10.1172/JCI143840
Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., Cassone, A. (2006). New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6:67–9. 10.1016/S1473-3099(06)70361-9
Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3:722- 727.
Tang, W., Cao, Z., Han, M., Wang,,Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., Chen, W., Wang, X., Yang, J., Lin, J., Zhao, Q., Yan, Y., Xie, Z., Li, D., Yang, Y., Liu, L., Qu, J., Ning, G., Shi, G., Xie, Q. (2020). Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv https://doi.org/10.1101/2020.04.10.20060558
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M. et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res 10.1038/s41422020-0282-0.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama [Internet]. 1–9. http://www.ncbi.nlm.nih.gov/pubmed/32031570.
Wiersinga W. J., Rhodes A., Cheng A. C., Peacock S. J., Prescott H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324 782–793. 10.1001/jama.2020.12839
Wilson N., Kvalsvig A., Barnard L. T., Baker M. G. (2020). Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg. Infect. Dis. 26 1339–1441. 10.3201/eid2606.200320
World Health Organization, https://covid19.who.int/region/amro/country/br, acesso em 1 de novembro de 2022.
Yan, Y., Zou. Z., Sun. Y., Li. X., Xu. K.F., Wei, Y., Jin, N., Jiang, C. (2013). Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 23:300-302.
Zhonghua, Jie He He Hu Xi Za Zhi, (2020). Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese], 43: E019. 10.3760/cma.j.issn.1001-0939.2020.0019.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382 727–733. 10.1056/NEJMoa2001017
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 José Eduardo Carvalho Saraiva ; Jorge Alberto de Sabóia Arruda Filho; Taynara Falkenstins Gois Mendes; Tânia Mara Silva Coelho; Melissa Soares Medeiros
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
